Abstracts tagged "fractures and osteoporosis"

Abstract Number: 2301 • 2018 ACR/ARHP Annual Meeting
Trend of Osteoporosis and Osteoporotic Fragility Fractures Among Select Autoimmune Rheumatologic Diseases: Results from National Inpatient Sample
Rashmi Dhital¹, Theresa Lynn², Pragya Shrestha³, Sijan Basnet⁴, Prakash Paudel⁵, Priyadarshani Sharma², Paras Karmacharya⁶ and Dilli Poudel⁷, ¹Reading Hospital-Tower Health System, West Reading, PA, ²Reading Hospital, West Reading, PA, ³Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁴Internal Medicine, Reading Hospital, West Reading, PA, ⁵Internal Medicine, Berkshire Medical Center, Pittsfield, MA, ⁶Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁷Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA
Background/Purpose: Rheumatologic diseases (RDs) have been associated with an increased risk of osteoporosis (OP) and osteoporotic fractures, however, most patients do not receive diagnosis and…
Abstract Number: 2302 • 2018 ACR/ARHP Annual Meeting
Forearm Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis
Nelson B. Watts¹, Robin K. Dore², Sanford Baim³, Gary Hattersley⁴, Greg Williams⁵, Yamei Wang⁴, Tamara D. Rozental⁶ and Meryl S. LeBoff⁷, ¹Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, ²Univ of California, Los Angeles, CA, ³Rush Medical College, Chicago, IL, ⁴Radius Health, Inc., Waltham, MA, ⁵Clinical Development, Radius Health, Inc., Waltham, MA, ⁶Beth Israel Deaconess Medical Center, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Wrist fractures are the most common fracture of the upper extremity and increase subsequent fracture risk in women with postmenopausal osteoporosis. Most wrist fractures…
Abstract Number: 2303 • 2018 ACR/ARHP Annual Meeting
Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density in Patients Treated with Abaloparatide Followed By Alendronate
Chad Deal¹, Bruce Mitlak², Yamei Wang², Lorraine A Fitzpatrick² and Paul D Miller³, ¹Cleveland Clinic, Shaker Heights, OH, ²Radius Health, Inc., Waltham, MA, ³Colorado Center for Bone Research, Lakewood, CO
Background/Purpose: Abaloparatide (ABL) is a selective activator of the PTH1 receptor signaling pathway that stimulates bone formation. In the ACTIVE Phase 3 study, ABL significantly…
Abstract Number: 2324 • 2018 ACR/ARHP Annual Meeting
Predictors of Refracture in Patients with Hip Fragility Fracture
Sara Ganhão^1,2, Miguel Guerra³, Francisca Aguiar^1,2, Georgina Terroso¹, Romana Vieira³, Diana Gonçalves⁴, Teresa Martins-Rocha^2,5, Raquel Ferreira^1,2, Ana Águeda^2,6, Tiago Meirinhos⁷, Eva Mariz^1,2, Raquel Lucas⁸, Miguel Bernardes^1,2, Carlos Vaz^1,2 and Lúcia Costa¹, ¹Rheumatology, Centro Hospitalar de São João, Oporto, Portugal, ²Faculty of Medicine, Oporto University, Oporto, Portugal, ³Rheumatology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, ⁴Rheumatology, Centro Hospitalar de Trás-os-Montes e Alto Douro, Vila Real, Portugal, ⁵Rheumatology Department, Centro Hospitalar de São João, Porto, Portugal, Oporto, Portugal, ⁶Rheumatology, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, ⁷Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal, Aveiro, Portugal, ⁸Public Health, Centro Hospitalar de São João, Oporto, Portugal
Background/Purpose: Hip fractures are associated with substantially elevated morbidity and mortality and thus represent a serious public health problem. The purpose of this study is…
Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Susan L. Greenspan¹, Lorraine A Fitzpatrick², Bruce Mitlak², Yamei Wang², Nicholas C. Harvey³, Chad Deal⁴, Felicia Cosman⁵ and Michael McClung⁶, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Radius Health, Inc., Waltham, MA, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Cleveland Clinic, Shaker Heights, OH, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Oregon Osteoporosis Center, Portland, OR
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…
Abstract Number: 1216 • 2017 ACR/ARHP Annual Meeting
Odontoid Fractures in the Elderly: An Unknown Osteoporotic Fracture?
Veronique Breuil¹, Lauren Natella², Nicolas Bronsard³, Jeremy Allia³, Laurent Hekayem⁴, Liana Euller Ziegler⁵ and Fernand De Peretti⁶, ¹Rheumatology department, Nice, France, ²Rheumatology, CHU Nice, nice, France, ³Orthopedic, CHU Nice, Nice, France, ⁴Emergency, CHU Nice, Nice, France, ⁵151 rte de St Antoine de Gines, CHU de Nice -Université Nice Sophia Antipolis, Nice, France, ⁶orthopedic, CHU Nice, Nice, France
Background/Purpose: Current WHO definition of osteoporosis excludes cervical fractures. However, in atraumatic odontoid fractures, mainly reported by orthopedic surgeons, bone status has not been described…
Abstract Number: 1886 • 2017 ACR/ARHP Annual Meeting
Continued Fracture Risk Reduction after 12 Months of Romosozumab Followed By Denosumab through 36 Months in the Extension of the Phase 3 Fracture Study in Postmenopausal Women with Osteoporosis
E Michael Lewiecki¹, Rajani V Dinavahi², Marise Lazaretti-Castro³, Peter R Ebeling⁴, J Adachi⁵, Akimitsu Miyauchi⁶, Evelien Gielen⁷, Cassandra E Milmont², Cesar Libanati⁸ and Andreas Grauer², ¹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ²Amgen Inc., Thousand Oaks, CA, ³Federal University of São Paulo, São Paulo, Brazil, ⁴Monash University, Melbourne, Australia, ⁵McMaster University, Hamilton, ON, Canada, ⁶Miyauchi Medical Center, Osaka, Japan, ⁷University Hospitals Leuven, Leuven, Belgium, ⁸UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is a monoclonal antibody that binds sclerostin with a dual effect, increasing bone formation and decreasing bone resorption. In the primary analysis…
Abstract Number: 1887 • 2017 ACR/ARHP Annual Meeting
Ten-Year Continued Nonvertebral Fracture Reduction in Postmenopausal Osteoporosis with Denosumab Treatment
S Ferrari¹, PW Butler², DL Kendler³, Paul D Miller⁴, C Roux⁵, AT Wang², Rachel B. Wagman² and EM Lewiecki⁶, ¹Geneva University Hospital, Geneva, Switzerland, ²Amgen Inc., Thousand Oaks, CA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Colorado Center for Bone Research, Lakewood, CO, ⁵Paris Descartes University, Paris, France, ⁶New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM
Background/Purpose: Treatment with denosumab (DMAb) for 3 years significantly reduces the incidence of nonvertebral fractures (NVFx; Cummings NEJM 2009). While there are limited data describing…
Abstract Number: 324 • 2016 ACR/ARHP Annual Meeting
A Placebo Controlled Trial of Vertebral Fill Technique Vertebroplasty for Acute Painful Osteoporotic Fracture (VAPOUR Trial)
Paul Bird^1,2, William Clark³, Terence Diamond⁴, Glen Schlaphoff⁵, Peter Smerdely⁶, Peter Gonski⁶ and Patrick McNeil⁷, ¹Medicine, University of New South Wales, Sydney, NSW, Australia, ²University of New South Wales, Sydney, Australia, ³Radiology, Southern Sydney Angiography, Sydney, Australia, ⁴Medicine, University of New South Wales, Sydney, Australia, ⁵Radiology, University of Sydney, Sydney, Australia, ⁶Aged Care, University of New South Wales, Sydney, Australia, ⁷Medicine, Macquarie University, Sydney, Australia
Background/Purpose: Evaluation of efficacy and safety of percutaneous vertebral fill technique vertebroplasty in subjects with acute vertebral fracture (symptom duration less than six weeks) .…
Abstract Number: 339 • 2016 ACR/ARHP Annual Meeting
Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study
Geórgea H. F. Torres¹, Luis F S Guzman², Jaqueline C. Alvarenga³, Levi H J Neto³, Valéria F. Caparbo³, Diogo S Domiciano³, Ricardo M. Oliveira⁴, Neusa H M Lopes² and Rosa M R Pereira⁵, ¹Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Cardiologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴RDO Diagnósticos Médicos, São Paulo, Brazil, ⁵Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil
Background/Purpose: Bone mineral density(BMD) by dual X-ray absorptiometry(DXA) is currently standard clinical tool for predicting osteoporotic fracture. However, DXA doesn’t allow studying abnormalities that predict different…
Abstract Number: 342 • 2016 ACR/ARHP Annual Meeting
Presence of Vertebral Fractures and Disc Disease in Post Menopausal Females with Height Loss As a Possible Screening Method for Osteoporosis
Nicola Berman¹, Gregory Chang² and Stephen Honig¹, ¹Rheumatology, New York University Department of Rheumatology, New York, NY, ²Radiology, New York University Department of Radiology, New York, NY
Background/Purpose: The presence of non-traumatic vertebral fracture can identify a patient who has clinical osteoporosis. However, approximately 75% of vertebral fractures are asymptomatic and as many…
Abstract Number: 372 • 2015 ACR/ARHP Annual Meeting
Prevalence of Atypical Fractures in a Tertiary Hospital
Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, César Antonio Egües Dubuc, Carlos Francisco Meneses Villalba, Vicente Aldasoro Caceres, Joaquin Belzunegui Otano and Gaspar De la Herran, Donostia University Hospital, San Sebastian, Spain
Background/Purpose: Actually, Biphosphonates are considered the first line treatment for osteoporosis. One of the side effects of the continuous treatment with these drugs is the…
Abstract Number: 2232 • 2015 ACR/ARHP Annual Meeting
Risk of Osteoporotic Fractures with Use of Cyclooxygenase-2 Inhibitors
Deepan Dalal¹, Devyani Misra², Christine Peloquin³, Tuhina Neogi⁴, Yuqing Zhang⁵, David T. Felson⁶ and Maureen Dubreuil⁷, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Medicine, Section of, BUSM, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Clinical Epidemiology, BUSM, Boston, MA, ⁵BUSM, Boston, MA, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁷Rheumatology, Boston VA HealthCare System, Boston, MA
Background/Purpose: In animal models, cyclo-oxygenase (COX)-2 stimulates osteoclasts through prostaglandin E2 (PGE2). Therefore, non-steroidal anti-inflammatory drugs (NSAIDs) preferentially inhibiting COX-2 (ie-coxibs) should prevent bone…
Abstract Number: 2800 • 2015 ACR/ARHP Annual Meeting
Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT
Sandra Gofinet Pasoto¹, Kristopherson Lustosa Augusto¹, Jackeline Couto Alvarenga², Liliam Takayama¹, Valéria Caparbo³, Ricardo M. Oliveira⁴, Eloisa Bonfá¹ and Rosa M R Pereira¹, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴RDO Diagnósticos Médicos, São Paulo, Brazil
Background/Purpose: To evaluate bone mineral density (BMD), microarchitecture, strength and prevalence of vertebral fractures (VF) in primary Sjögren's syndrome (pSS).Methods: We evaluated 71 female pSS…
Abstract Number: 369 • 2015 ACR/ARHP Annual Meeting
Incidence of Fragility Hip Fractures over 10 Years (2004-13) in Three UK Centres with Reference to Local Fracture Prevention (‘fracture liaison’) Service Activity
Gavin Clunie¹ and Jonathan Belsey², ¹Rheumatology, Cambridge University Hospital NHS Foundation Trust, Cambridge, United Kingdom, ²JB Medical, Sudbury, United Kingdom
Background/Purpose: Fracture Liaison Services systematically identify patients with fragility fracture and screen patients for osteoporosis and associated conditions and instigate evidence-based 'secondary' fracture prevention management.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].